Latest Oxigene Inc (OXGN) Headlines SmarTrend W
Post# of 9
Posted On: 03/13/2014 12:15:33 PM
Latest Oxigene Inc (OXGN) Headlines
SmarTrend Watching for Potential Pullback in Shares of OXiGENE After 77.27% Gain
Comtex SmarTrend(R) - Wed Mar 12, 5:13PM CDT
OXiGENE (NASDAQ:OXGN) traded in a range yesterday that spanned from a low of $4.14 to a high of $5.40. Yesterday, the shares gained 77.3%, which took the trading range above the 3-day high of $2.45 on volume of 29.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Oxigene Surprises With Positive Ovarian Cancer Study Success
at The Street - Wed Mar 12, 5:00AM CDT
A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.
UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 4:43PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 2:36PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p < 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Updated Time for Presentation at the ROTH Conference
GlobeNewswire - Tue Mar 11, 12:04PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company's presentation and webcast at the ROTH Capital Partners 26 Annual Growth Stock Conference will take place on Wednesday, March 12 at 9:30 a.m. PT at The Ritz Carlton Hotel in Dana Point California. Peter Langecker, M.D., PhD., Chief Executive Officer, will provide an update and corporate overview.
OXiGENE Announces Presentation at the ROTH Conference on March 11, 2014
GlobeNewswire - Fri Mar 07, 9:23AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the ROTH Capital Partners 26 Annual Growth Stock Conference on Tuesday, March 11, 2014 at 12:00 pm PT at The Ritz Carlton Hotel in Dana Point California.
OXiGENE Announces Full Year 2013 Earnings Conference Call and Webcast
GlobeNewswire - Tue Mar 04, 5:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2013 results on Tuesday March 18, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
OXiGENE Inc expects USD12m in public offering
M2 - Thu Feb 13, 5:22AM CST
Biopharmaceutical company OXiGENE Inc (NasdaqCM:OXGN) said on Wednesday that it expects an aggregate of about USD12m in a registered public offering of units at a price per unit of USD2.05.
OXiGENE, Inc. Announces $12 Million Public Offering
GlobeNewswire - Wed Feb 12, 7:56AM CST
OXiGENE, Inc. (Nasdaq:OXGN) today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately $12 million of units, in a registered public offering, at a price per unit of $2.05. Each unit consists of one share of common stock and 0.5 of a warrant to purchase a share of OXiGENE common stock. The warrants have an exercise price of $2.75 per share, shall be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to take place on or about February 18, 2014, subject to the satisfaction of customary closing conditions.
MEDIA ALERT: Advantest to Exhibit at SEMICON Korea 2014 in Seoul COEX February 12-14
Marketwire - Thu Feb 06, 2:05AM CST
Advantest Corporation (TSE: 6857) (NYSE: ATE)
OXiGENE Announces Presentation at BIO CEO Conference on February 11th
GlobeNewswire - Thu Jan 30, 5:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 16th annual BIO CEO & Investor conference on February 11, 2014 at 11:00 am ET at the Waldorf Astoria Hotel in New York City.
Tanager Announces Closing of Financing
Marketwire - Thu Jan 16, 8:31AM CST
Tanager Energy Inc. ("Tanager" or the "Corporation") (TSX VENTURE: TAN) advises that it has closed the first tranche of its previously announced financing of $250,000, subject to final approval from the TSX Venture Exchange. Pursuant to the non-brokered private placement, the Corporation issued 3,300,000 units at a price of $0.05 per share for gross proceeds of $165,000. Each Unit consists of one (1) common share and one (1) common share purchase warrant. Each warrant entitles its holder thereof to purchase one additional common share in the capital of Tanager for a period expiring on December 31, 2015, at an exercise price of $0.10 per common share. The remaining $85,000 of the financing will close on or before January 31, 2014. Net proceeds will be used for acquisition or farm-in of producing oil and gas properties and for general corporate purposes. The shares issued in connection with the private placement will be subject to a four month hold period that expires on May 16, 2014.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013 Includes an Overview of the Trial Numbers and their Recruitment Status
M2 - Fri Dec 13, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/wz3twf/hepatic_liver) has announced the addition of the "Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" provides data on the Hepatic (Liver) Tumor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic (Liver) Tumor. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic (Liver) Tumor. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Bayer AG -Celsion Corporation -Daiichi Sankyo Company, Limited -Eisai Co., Ltd. -GlaxoSmithKline plc -Instituto Cientifico y Tecnologico de Navarra -Jennerex Biotherapeutics, Inc. -Massachusetts General Hospital -Memorial Sloan Kettering Cancer Center -National Cancer Institute -National Institutes of Health Clinical Center -OXiGENE, Inc. -Sun Yat-sen University -The Techint Group -Tianjin First Central Hospital -Tokyo University of Science -Transgene SA -University of Zurich -Wake Forest University For more information visit http://www.researchandmarkets.com/research/wz...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OXiGENE Inc names Frederick W. Driscoll to board
M2 - Thu Nov 28, 4:14AM CST
Biopharmaceutical company OXiGENE Inc (NasdaqCM:OXGN) on Wednesday announced the appointment of Frederick W. Driscoll to its board of directors,.
SmarTrend Watching for Potential Pullback in Shares of OXiGENE After 77.27% Gain
Comtex SmarTrend(R) - Wed Mar 12, 5:13PM CDT
OXiGENE (NASDAQ:OXGN) traded in a range yesterday that spanned from a low of $4.14 to a high of $5.40. Yesterday, the shares gained 77.3%, which took the trading range above the 3-day high of $2.45 on volume of 29.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Oxigene Surprises With Positive Ovarian Cancer Study Success
at The Street - Wed Mar 12, 5:00AM CDT
A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.
UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 4:43PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 2:36PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p < 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Updated Time for Presentation at the ROTH Conference
GlobeNewswire - Tue Mar 11, 12:04PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company's presentation and webcast at the ROTH Capital Partners 26 Annual Growth Stock Conference will take place on Wednesday, March 12 at 9:30 a.m. PT at The Ritz Carlton Hotel in Dana Point California. Peter Langecker, M.D., PhD., Chief Executive Officer, will provide an update and corporate overview.
OXiGENE Announces Presentation at the ROTH Conference on March 11, 2014
GlobeNewswire - Fri Mar 07, 9:23AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the ROTH Capital Partners 26 Annual Growth Stock Conference on Tuesday, March 11, 2014 at 12:00 pm PT at The Ritz Carlton Hotel in Dana Point California.
OXiGENE Announces Full Year 2013 Earnings Conference Call and Webcast
GlobeNewswire - Tue Mar 04, 5:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2013 results on Tuesday March 18, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
OXiGENE Inc expects USD12m in public offering
M2 - Thu Feb 13, 5:22AM CST
Biopharmaceutical company OXiGENE Inc (NasdaqCM:OXGN) said on Wednesday that it expects an aggregate of about USD12m in a registered public offering of units at a price per unit of USD2.05.
OXiGENE, Inc. Announces $12 Million Public Offering
GlobeNewswire - Wed Feb 12, 7:56AM CST
OXiGENE, Inc. (Nasdaq:OXGN) today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately $12 million of units, in a registered public offering, at a price per unit of $2.05. Each unit consists of one share of common stock and 0.5 of a warrant to purchase a share of OXiGENE common stock. The warrants have an exercise price of $2.75 per share, shall be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to take place on or about February 18, 2014, subject to the satisfaction of customary closing conditions.
MEDIA ALERT: Advantest to Exhibit at SEMICON Korea 2014 in Seoul COEX February 12-14
Marketwire - Thu Feb 06, 2:05AM CST
Advantest Corporation (TSE: 6857) (NYSE: ATE)
OXiGENE Announces Presentation at BIO CEO Conference on February 11th
GlobeNewswire - Thu Jan 30, 5:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 16th annual BIO CEO & Investor conference on February 11, 2014 at 11:00 am ET at the Waldorf Astoria Hotel in New York City.
Tanager Announces Closing of Financing
Marketwire - Thu Jan 16, 8:31AM CST
Tanager Energy Inc. ("Tanager" or the "Corporation") (TSX VENTURE: TAN) advises that it has closed the first tranche of its previously announced financing of $250,000, subject to final approval from the TSX Venture Exchange. Pursuant to the non-brokered private placement, the Corporation issued 3,300,000 units at a price of $0.05 per share for gross proceeds of $165,000. Each Unit consists of one (1) common share and one (1) common share purchase warrant. Each warrant entitles its holder thereof to purchase one additional common share in the capital of Tanager for a period expiring on December 31, 2015, at an exercise price of $0.10 per common share. The remaining $85,000 of the financing will close on or before January 31, 2014. Net proceeds will be used for acquisition or farm-in of producing oil and gas properties and for general corporate purposes. The shares issued in connection with the private placement will be subject to a four month hold period that expires on May 16, 2014.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013 Includes an Overview of the Trial Numbers and their Recruitment Status
M2 - Fri Dec 13, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/wz3twf/hepatic_liver) has announced the addition of the "Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" provides data on the Hepatic (Liver) Tumor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic (Liver) Tumor. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic (Liver) Tumor. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Bayer AG -Celsion Corporation -Daiichi Sankyo Company, Limited -Eisai Co., Ltd. -GlaxoSmithKline plc -Instituto Cientifico y Tecnologico de Navarra -Jennerex Biotherapeutics, Inc. -Massachusetts General Hospital -Memorial Sloan Kettering Cancer Center -National Cancer Institute -National Institutes of Health Clinical Center -OXiGENE, Inc. -Sun Yat-sen University -The Techint Group -Tianjin First Central Hospital -Tokyo University of Science -Transgene SA -University of Zurich -Wake Forest University For more information visit http://www.researchandmarkets.com/research/wz...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OXiGENE Inc names Frederick W. Driscoll to board
M2 - Thu Nov 28, 4:14AM CST
Biopharmaceutical company OXiGENE Inc (NasdaqCM:OXGN) on Wednesday announced the appointment of Frederick W. Driscoll to its board of directors,.
(0)
(0)OXiGENE Inc (OXGN) Stock Research Links
Scroll down for more posts ▼